Research and experimental development on natural sciences and engineering
ZELLUNA IMMUNOTHERAPY AS
Revenue 2024
NOK 53,000
Operating profit
NOK −109.6m
Equity
NOK 36.0m
Incorporated
2016
Employees
9
Share capital
NOK 2.0m
Financials
Total operating revenue
Operating profit (EBIT)
Income statement
| Post | 2024 | Trend |
|---|---|---|
| Total operating revenue | 53k | |
| Total operating costs | 109.6m | |
| Operating profit (EBIT) | −109.6m | |
| Net financial items | 4.4m | |
| Profit for the year | −105.2m |
Balance sheet
| Post | 2024 | Trend |
|---|---|---|
| Total assets | 50.4m | |
| of which current assets | 33.1m | |
| Equity | 36.0m | |
| Total liabilities | 14.4m |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.